Khalili Mohammad Reza, Jahadi Hamid Reza, Karimi Mashaallah, Yasemi Masoud
Assistant Professor, Department of Ophthalmology, Poostchi Ophthalmology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Fars, Iran.
Professor, Department of Ophthalmology, Poostchi Ophthalmology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Fars, Iran.
J Clin Diagn Res. 2017 Jul;11(7):NC12-NC16. doi: 10.7860/JCDR/2017/24863.10253. Epub 2017 Jul 1.
Optimal management of infective keratitis is a formidable challenge and subject of ongoing studies. Recently, Collagen Cross-Linking (CXL) of the cornea has been considered to be a new effective therapeutic approach for resistant infectious keratitis.
Aim of the study was to evaluate the effectiveness of CXL with Ultraviolet-A (UV-A) and riboflavin for treatment of the refractory bacterial and Herpes Simplex Virus (HSV) keratitis.
In this prospective interventional study, eight patients with diagnosis of infectious keratitis who were referred to Khalili Hospital eye emergency room, between 2014 and 2015 were included in the study. There were six patients with bacterial keratitis and two patients with HSV keratitis; they were resistant to conventional treatment and underwent CXL. Response to the treatment was considered as good if rapid epithelialization and rapid decrease in stromal infiltration occurred.
Microbial culture in the bacterial keratitis group showed coagulase negative in two patients, in one patient, mixed infection in one patient and in two patients. Good response and rapid epithelialization and resolution of stromal infiltration were seen in the four out of six eyes. Two patients showed no response and underwent penetrating keratoplasty for eradication of infection. Furthermore, one patient showed a good response to CXL in the HSV keratitis group and another patient had a relative response but recurrence occurred.
Although, CXL seems promising in the treatment of patients with refractory bacterial keratitis, but in some cases, it is ineffective. CXL may be an alternative treatment for refractory cases of HSV keratitis but recurrence is possible.
感染性角膜炎的最佳治疗是一项艰巨的挑战,也是正在进行的研究课题。最近,角膜胶原交联(CXL)被认为是治疗耐药性感染性角膜炎的一种新的有效治疗方法。
本研究的目的是评估紫外线A(UV-A)联合核黄素的角膜胶原交联治疗难治性细菌性和单纯疱疹病毒(HSV)角膜炎的有效性。
在这项前瞻性干预研究中,纳入了2014年至2015年间转诊至哈利利医院眼科急诊室的8例诊断为感染性角膜炎的患者。其中6例为细菌性角膜炎患者,2例为HSV角膜炎患者;他们对传统治疗耐药,接受了角膜胶原交联治疗。如果角膜上皮迅速愈合且基质浸润迅速减轻,则认为治疗反应良好。
细菌性角膜炎组的微生物培养显示,2例凝固酶阴性,1例为 ,1例为混合感染,2例为 。6只眼中有4只眼出现良好反应,角膜上皮迅速愈合,基质浸润消退。2例患者无反应,接受穿透性角膜移植术以根除感染。此外,HSV角膜炎组1例患者对角膜胶原交联治疗反应良好,另1例患者有相对反应,但出现复发。
虽然角膜胶原交联在治疗难治性细菌性角膜炎患者方面似乎很有前景,但在某些情况下,它是无效的。角膜胶原交联可能是难治性HSV角膜炎病例的一种替代治疗方法,但可能会复发。